Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 7 Esophageal Neoplasms 4 Gastrointestinal Neoplasms 3 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Adenocarcinoma 2 Solid Tumor 1 Rectal Neoplasms 1 Patients With Advanced or Metastatic Solid Tumors 1 Pathologic Complete Response 1 Neoplasms, Unknown Primary 1 Nasopharyngeal Carcinoma 1 Locally Advanced Gastric Adenocarcinoma 1 Hand-Foot Syndrome 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 8 Trastuzumab 6 Docetaxel 5 pembrolizumab 4 Paclitaxel 4 Oxaliplatin 4 Fluorouracil 4 Cytarabine 4 Cyclophosphamide 4 Azacitidine 4 pertuzumab 3 Radiotherapy 3 Observation 3 Neoadjuvant Therapy 3 Epirubicin 3 Endoscopy 3 Cisplatin 3 Chemoradiotherapy 3 Capecitabine 3 130-nm albumin-bound paclitaxel 3 venetoclax 2 toripalimab 2 sargramostim 2 olaparib 2 durvalumab 2 cc-486 2 Tretinoin 2 Surgical Procedures, Operative 2 Standard of Care 2 Pemetrexed 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Complete Response × tegafur-gimeracil-oteracil × Clear all

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡